Effectiveness of BNT162b2 Vaccine in Adolescents during Outbreak of SARS-CoV-2 Delta Variant Infection, Israel, 2021

Emerg Infect Dis. 2021 Nov;27(11):2919-2922. doi: 10.3201/eid2711.211886. Epub 2021 Sep 27.


In Israel, the BNT162b2 vaccine against severe acute respiratory syndrome coronavirus 2 was approved for use in adolescents in June 2021, shortly before an outbreak of B.1.617.2 (Delta) variant-dominant infection. We evaluated short-term vaccine effectiveness and found the vaccine to be highly effective among this population in this setting.

Keywords: 2019 novel coronavirus disease; COVID-19; Delta variant; Israel; SARS-CoV-2; adolescents; coronavirus disease; respiratory infections; severe acute respiratory syndrome coronavirus 2; vaccine effectiveness; viruses; zoonoses.

MeSH terms

  • Adolescent
  • BNT162 Vaccine
  • COVID-19 Vaccines
  • COVID-19*
  • Disease Outbreaks
  • Humans
  • Israel / epidemiology
  • SARS-CoV-2
  • Vaccines*


  • COVID-19 Vaccines
  • Vaccines
  • BNT162 Vaccine